EUROTOX 2012

Scientific programme ver. 120601

Monday, June 18					
08.30-09.30	**Keynote lecture (K1):** **Revealing effects of early-life toxic metals exposure - a matter of toxicology, nutrition and epidemiology, Marie Vahter, Karolinska Institute, Sweden** **Chairs: Jyrki Liesivuori and Christina Rudén**				
09.30-10.00	**Coffee break**				
10.00-12.00	**Symposium S1** **Chemical exposure-related inflammation and cancer** **Chairs: Hans-Jeurgen Haussman,** Germany, and **Jyrki Liesivouri**, Finland	**Workshop W1** **Toxic exposures in the workplace and the environment: the contribution of biomonitoring to risk assessment** **Chairs: Martin Wilks,** Switzerland, and **Maurizio Manno,** Italy	**Symposium S2** **Innovative testing strategies to identify chemical respiratory sensitizers: present and future** **Chairs: Janine Ezendam,** The Netherlands, and **Werner Kobel**, Switzerland	**Workshop W2** **New target organ toxicities of environmental contaminants** **Chairs: Monica Lind,** Sweden, and **Aristidis Tsatsakis**, Greece	**Oral session OS1** **Mixtures** **Chairs: Cynthia de Wit** and **Bert-Ove Lund,** Sweden
10.00-10.20	Effect of alcohol on hepatocarcinogenesis and its interaction with other inflammatory hepatic diseases. H.K. Seitz, Germany	Critical scientific and ethical issues in biomonitoring for occupational and environmental risk assessment. M. Manno, Italy	Chemical respiratory sensitization: an important health problem, but how to identify and classify chemical respiratory sensitizers? J. Ezendam, The Netherlands	Low dose persistent organic pollutants and diabetes. D-H. Lee, South Korea	10.00-10.15 Co-exposure of Fusarium mycotoxins: In vitro myelotoxicity assessment on human. A-S. Ficheux
10.25-10.45	Pancreas inflammation and cancer. D.C. Whitcomb, USA	New knowledge on benzene metabolism in humans – implications for biological monitoring and risk assessment. S. Rappaport, USA	Cells and tissues encountered in the airways after inhalation of chemical respiratory sensitizers. F. Kuper, The Netherlands	Persistent organic pollutants and cardiovascular disease. L. Lind, Sweden	10.15-10.30 Mixtures of environmental contaminants and the metabolic syndrome. E. Lampa 10.30-10.45 Influence of interactions between polycyclic aromatic hydrocarbons on health effects. K. Dreij

10.50-11.10 11.15-11.35 11.40-12.00	The role of TGF-beta and TRAF6-TAK1-signalling pathways in tumour biology. M. Landström, Sweden Oxidative stress and inflammation: the link between COPD and lung cancer. I.M. Adcock, UK Molecular mechanisms linking chronic inflammation to cancer in the intestinal mucosa. P. Steinberg, Germany	Long-term surveillance of high-dose occupational dioxin exposure. D. Pelclová, Czech Republic Lead poisoning in pregnancy - sources, biomarkers, clinical features and management. S. Thomas, UK General discussion	*In vitro* tests for respiratory sensitizers. S. Remy, Belgium *In silico* approaches as a tool for identification of chemical respiratory sensitizers. D. Roberts, UK Alternative testing strategies for chemical respiratory sensitizers: pitfalls and opportunities. E. Roggen, Denmark	Obesogenic effects of endocrine disrupting chemicals. J. Legler, The Netherlands Bone as target for persistent organic pollutants. M. Lind, Sweden General discussion	10.45-11.00 Neurotoxicity of Chemical Mixtures Assessed with Multielectrode Array chips. B. Scelfo 11.00-11.15 Ammunition related metals - Combined toxicity of Antimony, Copper, and Lead. Per Leffler 11.15-11.30 Comparison of aggregate exposure approaches in the risk assessment of parabens. I. Gosens 11.30-11.45 Perinatal exposure to environmental contaminants affects bone properties in rats. L. Elabbas 11.45-12.00 Effects of combined occupational cadmium and lead exposure on renal biomarkers. R. Hambach
12.00-13.00	**LUNCH**				
13.00-14.00	**HESI lecture (K3): Exploring the Human Protein Atlas in the field of toxicology, Mathias Uhlén** **Chair: Elaine Faustman, University of Washington, United States**				

Monday, June 18					
	Highlighted lectures (K4 and K5) **Chairs: David Bell, ECHA, Helsinki and Ian Cotgreave, AstraZeneca, Sweden**				**Posters viewing**
14.00-14.45	**US EPA – ToxCast and the Tox21 program** **Richard Judson, US EPA**				
14.45-15.30	**State-of-the-science of endocrine disrupting chemicals, 2012** **Karen Kidd, Brunel University, United Kingdom**				
	Coffee break				
16.00-18.00	**Symposium S3** **Neurotoxicology of metals: mechanisms and clinical effects** **Chairs: Ronald Tjalkens,** USA, and **Sandra Ceccatelli,** Sweden	**Symposium S4** **Mechanisms of cell death and survival** **Chairs: Boris Zhivotovsky,** Sweden, and **Bernd Kaina,** Germany	**Workshop W3** **Mixture toxicity: Current approaches and future strategies** **Chair: Giuseppe Malinverno,** Italy and Andreas Kortenkamp United Kingdom	**Workshop W4** **The use of mechanistic data in chemical risk assessment** **Chairs: Angelika Tritscher,** Switzerland, and **Jean-Lou Dorne,** Italy	**Symposium S5** **From mechanisms of toxicity to biomarkers: addressing current and future needs in drug safety assessment** **Chairs: Ina Schuppe Koistinen,** Sweden, and **Eleni Aklillu**, Sweden Session sponsored by BHMF
16.00-16.20	Effects of neurotoxic metals on survival and differentiation of neural stem cells. S. Ceccatelli, Sweden	DNA damage-induced cell death. B. Zhivotovsky, Sweden	Mixture decision tree: Applications to real world mixtures. P. Price, USA	Overall weight of evidence approaches in chemical risk assessment. Angelika Tritscher, Switzerland	Safety Biomarkers: opportunities and challenges in drug discovery and development. I. Schuppe Koistinen, Sweden
16.25-16.45	From C. elegans to humans: translational mechanisms in the understanding of clinical manganese-induced neurodegeneration. M. Aschner, USA	Survival and death strategies in cells exposed to genotoxins. B. Kaina, Germany	Risk assessment of mixtures of pesticides. T.K. Reffstrup, Denmark	Toxicokinetic and dose response modelling in chemical risk assessment. D. Doerge, USA	Pharmacogenomic biomarkers for adverse drug reactions. E. Aklillu, Sweden

16.50-17.10	Developmental exposure to methylmercury impairs the glutamate-nitric oxide-cyclic GMP pathway and learning in rats. V. Felipo, Spain	Transcriptional inhibition by DNA damage as a trigger of cell death. M. Ljungman, USA	Low dose mixture effects of endocrine disrupters. A. Kortenkamp, UK	Population variability and uncertainty factors. J-L. Dorne, Italy	Current status and future perspectives of kidney safety biomarkers. J. Keenan, Ireland
17.15-17.35	Therapeutic uses of metals and minerals: the risk-benefit interface. J. Powell, UK	Mitochondrial involvement in cell death. S. Orrenius, Sweden	Speaker TBA	Application of the mode of action/human relevance framework to pesticide risk assessment. A. Boobis, UK	Current status and future perspectives of liver safety biomarkers. D. Antoine, UK
17.40-18.00	Neuroinflammatory responses to Manganese during development and aging. R. Tjalkens, USA	DNA repair pathways as target for cancer therapy. T. Helleday, UK	General discussion	General discussion	Current status and future perspectives of cardiovascular safety biomarkers R. Roberts, AstraZeneca, UK
	Informal gathering and discussions at the bars & Exhibitors presentations				
	City Hall reception				

Tuesday, June 19					
08.30-09.30	**Keynote lecture (K6):** **The new toxicology of sophisticated materials: Nanotoxicology and Beyond, Martin A. Philbert, University of Michigan, United States Chair: Ruth Roberts**				
09.30-10.00	**Coffee break**				
10.00-12.00	**Symposium S6** **Role of immunosurveillance in chemical carcinogenesis** **Chairs: Emanuela Corsini,** Italy, and **Nursen Basaran**, Turkey	**Symposium S7** **Large populations at risk? News on adverse health effects of low dose exposure to toxic metals** **Chairs: Lars Barregard and Agneta Åkesson,** Sweden	**Symposium S8** **From nanotoxicological research to safe management of nanomaterials** **Chairs: Bengt Fadeel,** Sweden **and Kai Savolainen,** Finland	**Workshop W5** **microRNAs as mechanistic indicators and biomarkers of drug-induced toxicity** **Chairs: Philippe Couttet,** UK, and **Jean-Charles Gautier,** France	**Oral session OS2** **Endocrine-disruptors** **Chairs: Helen Håkansson** and **Patrik Andersson,** Sweden
10.00-10.20	Immunomodulation and cancer: an overview. Rafael Ponce Amgen, Seattle, USA	Long term effects of metal accumulation through the nose-brain connection. R. Lucchini, Italy	Nanotoxicology: No small matter. B. Fadeel, Sweden	Application of Next Generation Sequencing (NGS) to the detection and analysis of miRNAs. D. Tonge, UK	10.00-10.15 Dietary cadmium exposure and risk of postmenopausal breast cancer. B. Julin
10.25-10.45	Oncogenic stress and immune activation. N. Basaran, Turkey	Kidney - critical organ for metals but methodological problems when interpreting urinary data. A. Bernard, Belgium	Environmental toxicity of engineered nanomaterials: Focus on aquatic species. R. Handy, UK	miRNAs as drivers of specific gene expression changes associated with tissue injury. P. Couttet, Switzerland	10.15-10.30 Cadmium as a placental endocrine disruptor in humans. M. Piasek
10.50-11.10	Chemical-induced immunosuppression and risk of cancer: experimental evidences. E. Corsini, Italy	Bone – is it the critical organ for cadmium exposure? Should we measure fractures, bone mineral density or biomarkers? A. Åkesson, Sweden	Hazardous properties of engineered nanomaterials: the pathogenic fibre paradigm. K. Donaldson, UK	The association of miRNAs with drug-induced kidney injury. J-C. Gautier, France	10.30-10.45 Endocrine modulatory effects of cadmium (CdCl2) in vivo. I. Ali
11.15-11.35	Prenatal arsenic exposure is associated with impaired thymic function in newborns. Sultan Ahmed, Sweden	Cardiovascular disease and diabetes – old and new findings regarding methyl mercury, cadmium, and lead. L. Barregård,	The potential human exposure to engineered nanomaterials: Facing the workplace challenge. K. Savolainen, Finland	miRNA-mediated changes in chemically-induced rat lung carcinogenesis, and their amelioration by chemopreventive agents. A. Izzotti, Italy	

11.40-12.00	General discussion	Sweden Biomonitoring: issues of analyses, nonlinear relationships, possible artefacts, and polymorphisms. I. Bergdahl, Sweden	The European regulatory perspective on engineered nanomaterials. B. Sokull-Klüttgen, Italy	General discussion	10.45-11.00 Premalignant epigenetic effects of arsenic and cadmium in drinking water and food. K. Broberg 11.00-11.15 Use of Organotypic Vaginal Tissue Model to Identify Endocrine Disrupting Chemicals. S. Letasiova 11.15-11.30 Toxicity with LXR agonists – problem solving activities for mechanistic understanding. P. Andersson 11.30-11.45 Endocrine disruptors target chondrogenesis in vitro. T.A. Auxietre 11.45-12.00 Bisphenol A at low doses: updated evidence on reproductive function. C. Rouselle

12.00-13.00	**EUROTOX-SOT debate (K7): Comparative Hazards: Chemicals in the Environment Are the Largest Risk to Human Health** **Eurotox Debater: David R Bell, ECHA Helsinki** **SOT Debater: Stephen Safe, Texas A&M University, USA** **Chair: Ruth Roberts, Vice President Eurotox Co-chair: Lois Lehman-McKeeman, SOT president elect**	
13.00-14.00	**Bo Holmstedt Memorial Foundation (BHMF) lecture (K8): Chemical allergy: The immune system is clearing the danger?** **Mark Pallardy, School of Pharmacy, University Paris-Sud. Chair : Herman Autrup**	

Tuesday, June 19

14.00-15.30	**Roundtable discussion (K 9) What is the next step for dealing with mixtures and low dose effects?** - A Kortenkamp, Brunel University - Michael Faust, BITZ – Bremer Innovations- und Technologie-Zentrum - Alan Boobis, SCHER - Peter Bos, RIVM - Jim Bridges, SCENIHR Chair: Mattias Öberg, Sweden			**Posters viewing**	
15.30-16.00	**Coffee break**				
16.00-18.00	**Symposium S9** **Unravelling the natural functions of the aryl hydrocarbon receptor and its proposed endogenous ligands** **Chairs: Agneta Rannug,** Sweden, and **Charlotte Esser**, Germany	**Symposium S10** **Read-across in risk assessment; problems or possibilities?** **Chairs: David Bell,** UK, and **Stéphane Vidry**, Belgium	**Symposium S11** **Pollution from drug manufacturing – assessing and managing risks in different regions of the world** **Chairs: D. G. Joakim Larsson**, Sweden and **Nancy Claude**, France	**Symposium S12** **New mechanistically based models for evaluation of drug induced liver injury: the IMI Predictive DILI project** **Chairs: Gerry Kenna,** UK, and **Percy Knolle,** Germany	**Oral session OS3** **Nanotoxicology** **Chairs: Herman Autrup,** Denmark and **Hanna Karlsson,** Sweden 16.00-16.15 Effect of silver and silica nanoparticles on gene expression in A549 cells. H. Autrup, Denmark

16.00-16.20	Striking functions of the aryl hydrocarbon receptor in cancer: from the control of cell migration to the activation of genome-wide insulators. P. Fernández-Salguero, Spain	An introduction to read-across for chemicals in food. G. Kass, Italy	Pharmaceutical pollution from Indian drug manufacturing – assessing risks for public and environmental health. D.G.J. Larsson, Sweden	Scope of the problem confronting Pharmas and outline of the IMI Predictive DILI project. G. Kenna, UK	16.15-16.30 Genotoxic and epigenetic effects of silver nanoparticles. H. Karlsson
16.25-16.45	Formation and background levels of the proposed endogenous AHR ligand 6-formylindolo[3,2-b]carbazole in vitro and in vivo. U. Rannug, Sweden	Chemical-specific metabolism and implications for toxicology and read-across – 1. H. Foth, Germany	Antibiotic pollution from Chinese drug manufacturing – effects on resistance development. Y. Zhang, China	Evaluation and adverse consequences of metabolic bioactivation. K. Park, UK	16.30-16.45 Long needle-like CNT cause severe pulmonary inflammation after pharyngeal aspiration. E. Rydman
16.50-17.10	AhR in differentiation and function of immune cells, with a focus on mucosal immunity. C. Esser, Germany	The application of large data sets of toxicological information to enable read-across – 1. S. Modi, UK	Pollution with opiates and other drugs from drug manufacturing in New York state, USA. P. Phillips, USA	Exploring hepatic transporter interactions. B. Stieger, Switzerland	16.45-17.00 Automated high content imaging for in vitro assessment of nanomaterial toxicity. G. Harris
17.15-17.35	Aryl hydrocarbon receptor in carcinogenesis. S. Safe, USA	Does read-across give enough certainty to ensure human health – 2. A. Boobis, UK	Adverse effects in wild fish living downstream from pharmaceutical manufacture discharges. W. Sanchez, France	Investigating immune mechanisms, in vitro and in vivo. P. Knolle, Germany	17.00-17.15 A comprehensive evaluation platform to assess nanoparticle toxicity in vitro. C. Hirsch
17.40-18.00	Biological effects of the proposed endogenous AHR ligand 6-formylindolo[3,2-b]carbazole. A. Rannug, Sweden	Application of a read-across framework provides high quality safety information – 2. K. Blackburn, USA	A path towards less pollution from drug manufacturing. R. Murray-Smith, UK	In vivo imaging of hepatic steatosis. H-P. Juretschke, Germany	17.15-17.30 Biocompatible micro cavity chip for noninvasive toxicity studies on the cellular level. Y. Kohl

					17.30-17.45 Use of 3D Tissue Models (EpiDerm, EpiAirway) for Nanotoxicology Applications. S. Letasiova 17.45-18.00 General Discussion

Wednesday, June 20					
08.30-10.30	**Workshop W6** **New tools in genetics and their application in toxicology** **Chairs: Jan Hengstler,** Germany, and **David Bell,** Finland	**Symposium S13** **Clinical toxicology: Are new insights into epidemiology and mechanisms of toxicity changing our approach to important poisonings?** **Chairs: Bruno Mégarbane,** France, and **Martin Wilks**, Switzerland	**Workshop W7** **Pharmaceuticals in the environment: occurrence, effects on wildlife, and how to reduce the levels** **Chairs: Christina Rudén and Jerker Fick,** Sweden	**Symposium S14** **Toxicological significance of pharmacogenomics in cancer treatment** **Chairs: Mumtaz Iscan**, Turkey, and **Philippe Beaune**, France	**Workshop W8** **CEFIC-LRI Innovative science awardees (2007-2010)** **Chairs: Bruno Hubesch**, Belgium, and **Herman Autrup**, Denmark
08.30-08.50	Genome-wide association studies (GWAS)- a tool for identifying genes involved in responses to toxic chemicals. F. Geller, Denmark	Analgesics toxicity: the dextropropoxyphene banning in Europe. N. Bateman, UK	A search for 120 pharmaceuticals in wild fish from five European countries. J. Fick, Sweden	Identification of genes predicting drug toxicity and response in the patient genome. A. Daly, UK	**2007**: Human neurospheres as 3D cellular systems for developmental neurotoxicity testing, Ellen Fritsche, Germany
08.55-09.15	Genotype at the NAT2 gene; phenotype and relevance for occupational bladder cancer. S. Selinski, Germany	Recreational stimulant overdrive: the mephedrone case. P. Hulten, Sweden	Synthetic progestins and glucocorticoids affect fish reproduction and physiology. S. Kugathas, UK	Genetic factors of anticancer drug toxicity. P. Beaune, France	**2009**: Using metabolomic biomarkers to bridge the gap between environmental exposure and human disease, H C Keun, UK
09.20-09.40	Analysis of the transcriptome and epigenome-state of the art and application to the detection of toxic responses in aquatic sentinel species. J. Kevin Chipman, UK	Psychotropic drug poisonings: involvement of the blood brain barrier. X. Déclèves, France	The continued threat of non-steroidal anti-inflammatory drugs to vultures. R. Cuthbert, UK	Drug/ Xenobiotic metabolizing enzyme polymorphisms and clinical outcome in lung cancer. M. Iscan, Turkey	**2010**: In quest of new fingerprints of exposure to VOC from consumer products, Juana Maria Delgado Saborit, UK
09.45-10.05	Deep sequencing identifies novel genes underlying a	Carbon monoxide poisoning; is there evidence for hyperbaric oxygen therapy? F. Lind,	Regulatory perspectives on pharmaceuticals in the environment. M. Ågerstrand,	Pharmacogenomics in efficacy and toxicity of endocrine therapy in breast cancer. M.	

10.10-10.30	hepatic response to toxins. D. Bell, Finland General discussion	Sweden Cardiac glycoside overdose: is Fab fragment therapy life-saving? B. Mégarbane, France	Sweden General discussion	Schwab, Germany Pharmacogenetic aspects of taxane therapy toxicity. R. Van Schaik, The Netherlands	
10.30-11.00	**Coffee break**				

11.00-13.00	**Workshop W9** **Cellular tight junctions – a target for nephrotoxins** **Chair: Kevin Chipman,** UK	**Workshop W10** **New in vitro methods for assessment of developmental toxicity endpoints** **Chairs: Eugenio Vilanova,** Spain, and **Mojmir Mach,** Slovak Republic	**Symposium S15** **Dose-response relationship and receptor-mediated toxicology** **Chairs: Remi Bars,** France, and **Ben van Ravenzwaay,** Germany Session sponsored by ECETOC.	**Symposium S16** **Stem cells in drug discovery and development** **Chairs: Jens Reinhart,** Germany, and **Paul Duffy,** UK
11.00-11.20	Speaker:TBA	New in vitro methods for developmental toxicity. Workshop introduction. E Vilanova, Spain	Endocrine toxicity mediated through the ER, AR steriodogenic and AhR pathways. Case studies and dose response relationship. E. Gray, USA	Introduction/Overview – Stem cells as tools in screening/problem solving and Regenerative Medicine. P. Duffy, UK
11.25-11.45	Speaker: TBA	Application of Micro Electrode Arrays (MEAs) as an Emerging Technology for in vitro Developmental Neurotoxicity Testing. A. Price, Italy	Genomic dose-response modeling to inform key events in a mode-of-action risk assessment. R. Thomas, USA	Stem cell approaches for early drug discovery screening. F. Bonner, UK
11.50-12.10	EPAC-RAP signalling protects against Cisplatin-induced apoptosis of renal proximal tubular cells. G Benedetti, The Netherlands	Gene expression markers of early stage of cell differentiation as endpoints for shortening in vitro developmental toxicity assays. M. Sogorb, Spain	Endocrine toxicity - mediated through the AR and evaluation of dose-response relationship. R. Bars, France	SC 3D culture/co-cultures/Bioreactors. D. Hay, Scotland
12.15-12.35	KIM-1 expression with segment-specific nephrotoxicants. A. Trevisan, Italy	Proteomic versus genomic markers for cell differentiation and embryotoxicity. A.H. Piersma, The Netherlands	Dose-response relationship toxicity in CAR/PXR humanised mouse. C. Elcombe, UK	Stem cells as advanced therapeutics. J. Sinden, UK
12.40-13.00	General discussion	Molecular and cellular endpoints: practical relevance and challenges in developing in vitro endpoints for developmental and reproductive toxicity. E.M. Faustman, USA	Dose-response relationship in toxicity following Ah receptor activation in animal models. D. Schrenk, Germany	Safety assessment and regulations. J. Reinhardt, Germany
13.00-14.00	**Closing ceremony**			